bioihbjkbjnl/mcl2 huggingface dataset:
Prevalence of Musculoskeletal Pain and Its Impact on Quality of Life and Functional Exercise Capacity in Patients With Pulmonary Arterial Hypertension
Condition: Pulmonary Arterial Hypertension
MeSH terms: Musculoskeletal Pain; Pulmonary Arterial Hypertension; Familial Primary Pulmonary Hypertension; Hypertension
Study type: Observational

Summary: 
      Prevalence of musculoskeletal pain and its impact of quality of life and functional exercise
      capacity will be evaluated in patients with pulmonary arterial hypertension.
    

Detailed description: 
      Although main symptoms of pulmonary arterial hypertension (PAH) include shortness of breath
      and exercise intolerance, patients may also experience symptoms related to musculoskeletal
      system such as muscle fatigue or pain. Due to insufficient cardiac output and chronic
      arterial hypoxemia, oxygen cannot be delivered to skeletal muscles sufficiently, especially
      during exertion. In addition, inflammation, which is thought to play an important role in
      pulmonary vascular remodeling and disease pathophysiology in these patients, affects skeletal
      muscles as well. Increased sympathetic tone in PAH restricts the perfusion of skeletal muscle
      by increasing peripheral vascular resistance. With the addition of physical inactivity to all
      these factors, skeletal muscle metabolism is further impaired. Furthermore, drugs used for
      the treatment of PAH may induce musculoskeletal pain as a side effect. Musculoskeletal pain
      is one of the most important factors impairing individual's quality of life, regardless of
      whether there is an underlying disease. Our aim in this study is to evaluate pain prevalence
      in the musculoskeletal system over 9 body regions, to compare the pain prevalence of patients
      using different types of PAH drugs and to examine impact of musculoskeletal pain on quality
      of life and functional capacity in patients with PAH.
    

Intervention name(s): Evaluation of musculoskeletal pain prevalence; Evaluation of quality of life; Evaluation of functional exercise capacity; Evaluation of physical activity level
Intervention type(s): Other; Other; Other; Other
Intervention description(s): Prevalence of musculoskeletal pain will be evaluated over 9 body regions using The Nordic Musculoskeletal Questionnaire.; Quality of life will be evaluated using The EmPHasis-10 questionnaire and The Minnesota Living with Heart Failure Questionnaire.; Functional exercise capacity will be evaluated using 6-min walk test.; Physical activity level will be evaluated using International Physical Activity Questionnaire- Short Form
Observational model: Other
Time perspective: Prospective
Sampling method: Probability Sample
Study population: 
        Adult patients diagnosed with pulmonary arterial hypertension
A Study of LY3023703 Testing Pain Relief After Wisdom Teeth Removal
Condition: Acute Pain
MeSH terms: Acute Pain
Study type: Interventional
Phase: Phase 2

Summary: 
      The main purpose of this study is to test if a single dose of LY3023703 relieves pain after
      wisdom teeth removal. The study will last about one week for each participant, not including
      screening.
    


Intervention name(s): Placebo; LY3023703; Celecoxib
Intervention type(s): Drug; Drug; Drug
Intervention description(s): Administered orally; Administered orally; Administered orally
Other intervention name(s): LY3023703 phosphate
Intervention MeSH terms: Celecoxib
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Keywords: Wisdom tooth extraction
A Safety Study of Ginkgolides Meglumine Injection in the Treatment of Ischemic Stroke.
Condition: Ischemic Stroke
MeSH terms: Stroke; Ischemic Stroke; Cerebral Infarction; Ischemia
Study type: Interventional
Phase: Phase 4

Summary: 
      The aim of this study is to evaluate the safety of Ginkgolides Meglumine Injection in the
      treatment of ischemic stroke with Syndrome of Intermingled Phlegm and Blood Stasis.
    

Detailed description: 
      Ginkgolides Meglumine Injection was jointly developed by China Pharmaceutical University and
      Jiangsu Kanion Pharmaceutical Co., Ltd. Its pharmacal ingredients are ginkgo lactones ,
      ginkgo lactone B, ginkgo lactone K, etc; Excipients for meglumine, citric acid, sodium
      chloride. It is used to treat stroke (mild-to-moderate cerebral infarction) in recovery
      phlegm and Syndrome of Intermingled Phlegm and Blood Stasis.

      The aim of this study is to evaluate the safety of Ginkgolides Meglumine Injection in the
      treatment of ischemic stroke with Syndrome of Intermingled Phlegm and Blood Stasis.
    

Intervention name(s): Ginkgolides Meglumine Injection
Intervention type(s): Drug
Intervention description(s): 25mg, intravenous drip, once a day. Number of Cycles: 14 days.
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: ischemic stroke; safety; Ginkgolides Meglumine Injection
Indicated Prevention With At-Risk Gamblers
Condition: Gambling; Pathological Gambling; Problem Gambling
MeSH terms: Gambling
Study type: Interventional
Phase: Phase 2

Summary: 
      The overall purpose of this study is to reduce the prevalence of gambling risk in college
      students by evaluating the effectiveness of different treatments in reducing gambling
      behavior and related negative consequences.
    

Detailed description: 
      Participants in this study will be randomly assigned to a personal feedback intervention
      (PFI) or assessment only for 3 years. The PFI intervention will be delivered in a single
      session. Measures will include the NORC DSM Screen for Problem Gambling (NODS), the South
      Oaks Gambling Screen (SOGS), Gambling Quantity and Perceived Norms, Perceived Injunctive
      Gambling Norms, Gambling Problems Index, gambling frequency, attitudes and beliefs about
      gambling and self-control, readiness to change, gambling expectancies, gambling motives,
      gambling risk perception, psychiatric symptoms, assertiveness, coping skills, substance use,
      alcohol-related problems, self-determination, and social desirability.
    

Intervention name(s): Personalized Feedback Intervention; Cognitive Behavioral Intervention
Intervention type(s): Behavioral; Behavioral
Intervention description(s): Sessions lasted for 60-90 minutes and used Motivational Interviewing (MI) to facilitate discussion of feedback from participants' survey responses. Sessions began with open-ended questions about contextual factors associated with participants' gambling, then review of each feedback section: gambling pattern; perceived gambling norms; positive expectancies and negative consequences of gambling; beliefs about control over gambling; and situational self-efficacy to avoid gambling. Participants were encouraged to consider the feedback in light of their personal goals. All participants received a copy of their feedback, a list of skills for limiting gambling and a resource/referral list.; Participants completed either six weekly 1-hour sessions or attend four sessions containing the same content. Sessions covered functional analysis and gambling triggers; challenging cognitive distortions, with emphasis on illusions of control; coping with triggers; assertiveness; and relapse prevention. Participants received a pamphlet covering each week's topic (which was reviewed with the participant if a session was missed), as well as homework sheets and gambling diaries. CBI participants were asked to refrain from gambling for the duration of the group to provide an opportunity to practice and develop skills applicable to gambling and other behavior change situations.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Prevention
Keywords: Gambling; Pathological Gambling; Problem Gambling; College Students; Prevention
High-Resolution Solid-State Manometry of the Effect of Succinylcholine on Barrier Pressure
Condition: the Effect of Succinylcholine on Barrier Pressure
Study type: Interventional
Phase: Phase 4

Summary: 
      The lower esophageal sphincter（LES）plays a key role in preventing regurgitation and
      aspiration. The pressure of LES partly comes from striated muscles derived from the crural
      portion of the diaphragm. The effect of succinylcholine on esophagogastric junction during
      anesthesia induction is not clear. We conducted a prospective interventional study on the
      effect of succinylcholine on the barrier pressure (BrP) of the esophagogastric junction.
    

Detailed description: 
      14 patients participated in the study. Propofol and succinylcholine were used for anesthesia
      induction. High-resolution solid-state manometry (HRM) was used to monitor the changes of the
      LES pressure and the intragastric pressure (IGP).The administration of propofol could
      significantly increase the LES pressure during end expiration and during inspiration. The
      application of succinylcholine had no effect on the LES pressure during end expiration, but
      significantly reduced the LES pressure during inspiration. Propofol had no effect on BrP.
      After the application of succinylcholine, BrP decreased significantly during inspiration.

      Propofol significantly increased the LES pressure. Succinylcholine significantly reduced the
      pressure of LES and BrP during inspiration.
    

Intervention name(s): Succinylcholine
Intervention type(s): Drug
Intervention description(s): 1.5mg/kg was given intravenously
Other intervention name(s): propofol
Intervention MeSH terms: Propofol; Succinylcholine
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Prevention
Keywords: lower esophageal sphincter; intragastric pressure; succinylcholine
A Follow-up Evaluation Study of PRI-724-1101
Condition: Hepatitis C Virus-infected Cirrhosis
MeSH terms: Hepatitis C; Hepatitis; Liver Cirrhosis; Fibrosis
Study type: Observational [Patient Registry]

Summary: 
      The purpose of this study To evaluate the safety and efficacy of PRI-724 administration in
      patients with cirrhosis due to hepatitis C by 12-month follow-up.
    

Detailed description: 
      This is a single-center, nonintervention, open-label, observational study in subjects who
      received the study drug (identification code: PRI-724) in Study 1101 to follow up the safety
      and disease condition of cirrhosis after administration for 12 months.

      In Study 1101, one cycle consisted of 2 weeks with one-week continuous i.v. administration of
      PRI-724 followed by a one-week observation period. Treatment with a total of six cycles
      (duration of treatment, 12 weeks) was performed.

      In this study, the subjects in each cohort in Study 1101 (PRI-724 dose: Cohort 1, 10
      mg/m2/day; Cohort 2, 40 mg/m2/day; Cohort 3, 160 mg/m2/day) were followed up and observed for
      12 months after administration.

      In Study 1101, target number of subjects was 6 subjects in each cohort, a total of 18
      subjects. However, the number of registered subjects was 7 subjects in Cohort 1, 7 subjects
      in Cohort 2, and 2 subjects in Cohort 3, a total of 16 subjects. Safety analysis set was 6
      subjects, 6 subjects, and 2 subjects, respectively, a total of 14 subjects. Target number of
      the subjects in this study was the same as that in Study 1101; however, of the subjects in
      Study 1101, 5 subjects in Cohort 1 and 3 subjects in Cohort 2 consented to participate in
      this study (Study 1102).
    

Intervention name(s): PRI-724
Intervention type(s): Drug
Other intervention name(s): CBP-beta-catennin inhibitor; OP-724
Observational model: Other
Time perspective: Prospective
Sampling method: Probability Sample
Study population: 
        PRI-724 administration in patients with cirrhosis due to hepatitis C
Evaluation of the Efficacy and Safety of Curalin as Add-On Therapy in Adults With Type 2 Diabetes Mellitus
Condition: Type2 Diabetes
MeSH terms: Diabetes Mellitus; Diabetes Mellitus, Type 2
Study type: Interventional
Phase: Phase 2

Summary: 
      Evaluation of Efficacy and Safety of Curalin As Add-On Therapy in Adults With Type 2 Diabetes
      Mellitus
    

Detailed description: 
      A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy
      and Safety of Curalin As Add-On Therapy in Adults With Type 2 Diabetes Mellitus
    

Intervention name(s): Curalin
Intervention type(s): Dietary Supplement
Intervention description(s): Supplement capsules, 2 capsules, 3 times a day after meals. Placebo: matching placebo capsules, 2 capsules, 3 times a day after meals.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary purpose: Treatment
Keywords: Diabetes; Type 2 Diabetes; placebo; Curalin; CuraLife; Momordica Charantia; Gymnema Sylvestre; Trigonella Foenum Graecum; Curcuma Longa; Emblica Officinalis; Swertia Chirata; Picrorhiza Kurroa; Syzygium Cumini/ Eugenia Jambolana; Cinnamomum Zeylanicum
Dose Ranging Study for Indacaterol in Japanese Asthma Patients
Condition: Asthma
MeSH terms: Asthma
Study type: Interventional
Phase: Phase 2

Summary: 
      This study was designed to provide data about the safety and efficacy of 3 doses of
      indacaterol (150, 300, and 600 µg) in Japanese asthma patients so that an optimal dose, or
      doses, could be chosen for testing in later studies.
    


Intervention name(s): Indacaterol; Placebo; Salmeterol
Intervention type(s): Drug; Drug; Drug
Intervention description(s): In the morning, powder filled capsules inhaled using a single dose dry powder inhaler (SDDPI).; Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).; Salmeterol 100 μg total dose taken on Day 1. 50 μg in the morning and 50 μg twelve hours post initial dose inhaled via Diskus®, an inhalation device for Salmeterol.
Other intervention name(s): QAB149; Serevent
Intervention MeSH terms: Salmeterol Xinafoate
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: asthma; QAB149; indacaterol; long acting β2-agonist; bronchodilator
Comparison of Lasers in the Treatment of Scars
Condition: Scar
Study type: Interventional

Summary: 
      The purpose of this study is to compare the 1550-nm non-ablative Fraxel laser (referred to as
      Fraxel Laser in this application) to the ablative 10,600-nm carbon dioxide fractional laser
      (referred to as CO2 Laser in this application) to determine if one is superior to the other
      in improving the appearance of scars over a series of three treatments. In addition, the
      investigators hope to identify a more cost-effective method to improve the appearance of
      scars caused by surgery or trauma.
    

Detailed description: 
      This study will be accomplished through a controlled split-scar study design whereby half of
      the scar will be treated with the Fraxel Laser and the other half of the scar will be treated
      with the CO2 Laser. This study is a blinded, prospective comparative, split-scar study
      whereby 100 participants will be recruited, enrolled and followed for a period of 9 months.
      The study population will include male and female participants, age 18 and over with scars
      secondary to surgery or trauma on any part of the body. The study will recruit participants
      with light colored skin, Fitzpatrick Type I-IV, because colored skin has a significantly
      higher risk of keloid scarring. The scar must measure a minimum of 4 cm in length to
      accommodate for the split-scar treatment. The participants will undergo laser treatments on
      Visit 1, Visit 2 and Visit 3 and each visit will be 4 weeks apart. The participants will
      return for evaluation and follow-up 3 months and 6 months following the last laser treatment.
      At each visit, photographs will be taken using identical camera settings, lighting and
      participant positioning. Evaluation of the scars will be completed by the participants and by
      blinded dermatology physicians. Participants will use a complete visual analogue scale at
      each visit, the Patient and Observer Scar Assessment Scale (POSAS) and a satisfaction score.
    

Intervention name(s): Fraxel Laser; CO2 Laser
Intervention type(s): Device; Device
Intervention description(s): One half of the scar is treated with Fraxel Laser; One half of the scar is treated with CO2 Laser.
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Volume Kinetics for Hyperoncotic Albumin in Burn Patients as Well as for Healthy Subjects
Condition: Burns
MeSH terms: Burns
Study type: Interventional
Phase: Phase 4

Summary: 
      Treatment with colloidal solutions has during long time been a cornerstone within intensive
      care. Lately, doubts have been raised about synthetic colloids, and the natural albumin has
      been used more and more.

      One of these solutions is the hyperoncotic "Albumin 20%". However there are still many
      aspects of the physiological effects of hyperoncotic albumin, that are not known. In this
      study physiological effects will be studied in burn patients and healthy subjects. The
      colloid osmotic pressure and the increase of the plasma volume will be measured in 15 healthy
      subjects and in 15 burn patients. The effect on the plasma volume will be studied using
      hemoglobin as a marker of dilution. Colloids osmotic pressure and albumin concentration will
      be measured directly and urin production will also be measured. Blood samples will be
      collected during 4 to 5 hours to achieve a profile over the changes.
    

Detailed description: 
      Healthy individuals are asked to refrain from eating and drinking the night before the study.
      Two hours before study start, the subjects may take a sandwich and a glas to drink. Patients
      will also be asked to keep the same rules unless they receive parenteral nutrition. Shortly
      before the study, the subjects are asked to leave an urine sample.

      After 15 minutes of rest the first bood samples are taken. An infusion 3 ml/kg bodyweight
      Albumin 20% is given during 30 minutes. The first hour after study start (start of infusion)
      blood samples are taken every 10 minutes. The following 4 hours another 9 blood samples are
      collected. Hemoglobin, albumin and colloidosmotic pressure will be measured at every
      occasion.

      C-reactive protein, interleukin-6, Syndecan -1 as well as heparan sulfate, will be measured
      before, after 1 hour and 5 hours after study start.

      The total volume of blood collected will be 150 ml. If the study subjects have a low urin
      output, acetated Ringers will be given at the end of the study. Liberal fluid intake is
      recommended the same day and the next.
    

Intervention name(s): Albumins
Intervention type(s): Drug
Intervention description(s): Infusion of 3ml/kg bodyweight of hyperoncotic albumin 20% during 30 minutes.
Other intervention name(s): Albumin 20%
Allocation: Non-Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Proprioceptive Thumb Exercises Program in Patients With Carpometacarpal Joint Osteoarthritis
Condition: Thumb Osteoarthritis
MeSH terms: Osteoarthritis
Study type: Interventional

Summary: 
      Osteoarthritis (OA) is a chronic and prevalent joint disorder with great impact on quality of
      life and high economic burden. Although a number of conservative therapies have proven to be
      effective for the management of hand OA, only modest treatment effects were reported for most
      individual interventions. The aim of the proposed study is to assess the effect of
      proprioceptive training on pain, function and sense perception in patients with
      carpometacarpal osteoarthritis (CMC OA).
    

Detailed description: 
      A randomized, controlled, single-center, double-blind, clinical trial, with 1:1 allocation
      ratio, will be carried out involving patients diagnosis of CMC joint OA grade 1-2 (aged 18
      years and above). Both assessor and statistician will remained blinded. The research
      diagnostic criteria for carpometacarpal joint osteoarthritis will be used to assess all
      individuals who agree to participate. Based on the clinical and radiological findings, the
      participants will be classified by a rheumatology. Those with CMC OA grade 2-3 will be
      included in the study.

      Standard conservative thumb CMC joint OA treatments will received for both the control and
      experimental groups for a period of 12 weeks. The experimental group will received a
      proprioceptive training program during the same intervention period, which will be conducted
      twice weekly (24 sessions).

      The severity of pain with activity will be measured according to the visual analog scale
      (VAS). QuickDASH questionnaire will be used to measure upper extremity function. Patient's
      occupational performance will be measured with the Canadian Occupational Performance Measure
      (COPM) and proprioception with Joint position sense (JPS) testing. All outcome measures will
      be collected at baseline, immediately following the intervention at 4 weeks and at 12 weeks
      following the end of the intervention.

      Participation in the study will be voluntary and patients will be included if they satisfied
      specific inclusion criteria.

      All procedures will be follow in accordance with the ethical standards of the responsible
      committee on human experimentation (institutional and national) and with the Helsinki
      Declaration. All participants will sign a written informed consent in accordance with
      guidelines approved by the local ethics committee.
    

Intervention name(s): Proprioceptive thumb exercises.
Intervention type(s): Other
Intervention description(s): Exercises for recognition of thumb position and thumb force sense.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary purpose: Treatment
Keywords: Thumb pain; Thumb proprioception; Osteoarthritis